Sequent Scientific has informed that the Company has entered into a Business transfer agreement with Solara Active Pharma Sciences Limited to acquire the EU-GMP API facility at Mahad (Mahad facility). The total consideration for the unit would be Rs 46.4 crores on an Enterprise Valuation basis. The acquired Mahad facility compliments the current manufacturing at Vizag (USFDA approved) and Tarapur (Intermediates).
The above information is a part of company’s filings submitted to BSE.